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Problem identification: The need for 
cognitive impairment screening
• Cognitive impairment is defined as a noticeable and measurable decline in memory and 
thinking skills1
• Approximately 80% of people with amnestic cognitive impairment go on to develop 
Alzheimer’s disease, the most common form of dementia, within seven years2
• At present, cognitive impairment and dementia are clinical diagnoses1
• While it is an active area of research, there are currently no neuroimaging, laboratory, or genetic 
testing means of diagnosis
• Per the USPSTF, 29-76% of patients with dementia in the primary care setting are 
undiagnosed3
• Cognitive impairment screening can lead to earlier detection and thus the ability to make 
diagnostic and treatment decisions, manage comorbid conditions, treat reversible causes of 
dementia, and plan for the future
• Cognitive impairment screening is mandated as part of the Medicare Annual Wellness Visit
• Many practitioners do not routinely screen for cognitive impairment and there is no 
consensus screening tool4
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Public health considerations: The rising 
cost of dementia
• Globally, 46 million people have dementia5
• The global economic cost of Alzheimer’s disease is estimated at over 600 billion 
dollars annually1
• Alzheimer’s disease is the 6th leading cause of death in the United States2
• The number of people with Alzheimer’s disease in the US is expected to triple by 
20506
• In 2018, 16.3 million individuals provided 18.5 billion hours of unpaid dementia 
care1
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Community perspective: Why screen for 
cognitive impairment?
“[Screening for cognitive impairment and dementia] is important from the perspective of 
early treatment intervention, and also to assist patients and their families as they plan for 
the future, and make decisions about how they want to conduct the rest of their lives”
“The rationale for the screening tool was focused by the advent of the [Affordable Care Act] 
which mandates screening for cognition as part of the Medicare Annual Wellness [Visit]”
• William Pendlebury, M.D., Director of the UVMMC Memory Center
“Benefits include earlier detection for services”
• Sean Maloney, M.D., Medical Director at Colchester Family Medicine
“I have been surprised at some patients’ significant deficits that I might not otherwise have 
been aware of as early”
• Candace Fraser, M.D., Colchester Family Medicine, Family Medicine Clerkship Director
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Community perspective: Why screen with 
the Vermont Mini-Cog?
“The addition of category fluency was my idea to broaden the cognitive domains 
tested. Category fluency is believed to test for both verbal ability (temporal lobe) 
and executive control (frontal lobe). So, its addition does make the screening tool 
more complete”
• William Pendlebury, M.D., Director of the UVMMC Memory Center
• The Mini-Cog© screening tool, from which the Vermont Mini-Cog was developed, evaluates 
encoding and short-term recall (three-word recall) and visuospatial functioning (clock drawing)
The UVMMC Medical Home Leadership team is working on building a new template 
for the Medicare Annual Wellness Visit. They have chosen the Vermont Mini-Cog as 
the standardized screening tool that will be used at UVMMC Family Medicine and 
Internal Medicine clinics in the future
• Information from Alicia Jacobs, M.D., Colchester Family Medicine, Vice Chair for Family 
Medicine Clinical Operations
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Community perspective: What barriers 
exist to cognitive impairment screening?
“The barrier [is] time. It can take nearly an entire visit just to do the MoCA and 
discuss the results and plan”
• Melissa Barrup, APRN, Colchester Family Medicine
• The Montreal Cognitive Assessment (MoCA) is another cognitive impairment screening 
tool
“[Barriers are that screening] takes time, it’s one more thing on the long list of 
screenings we are expected to do, and can annoy people”
• Marga Sproul, M.D., Colchester Family Medicine
“Not in Epic”
• Travis Robillard, PA, Colchester Family Medicine
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Intervention and methodology
• Researched the background of the Vermont Mini-Cog and the current status of cognitive 
impairment screening at UVMMC
• Surveyed Colchester Family Medicine providers about their current cognitive impairment 
screening practices, the barriers to screening that they encounter, and the benefits and 
harms of screening that they perceive
• Developed and presented a training module to Colchester providers that provided 
contextual information on cognitive impairment screening in general and the Vermont Mini-
Cog specifically
• The training addressed the barriers and perceived benefits and harms noted by providers
• Informational materials including administration and scoring instructions and a video on how 
to perform the screening were created
• Training module link: 
https://drive.google.com/drive/folders/1z7QPr4c9JCCLHmzoNf6NI2VqvljyXQpu?usp=sharing
• Providers who attended the lunchtime presentation of the training module were provided 
an anonymous paper survey assessing their response
5
Results
• 6/7 providers surveyed indicated that they are now very or extremely likely to 
screen patients for cognitive impairment during Medicare Annual Wellness Visits
• 7/7 providers indicated that they are more or much more likely to screen for 
cognitive impairment compared to their current practices
• 5/7 providers indicated that they are now very or extremely likely to use the 
Vermont Mini-Cog as their cognitive impairment screening tool
• 5/7 providers agree or strongly agree with the statement that routine cognitive 
impairment screening is beneficial to patients
• Training module created and distributed for future use at Colchester Family 
Medicine
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Evaluation of effectiveness
Initial results:
• All surveyed providers indicated that they are more likely to screen for cognitive impairment after participating in the training
• The majority of providers surveyed are very likely to use the Vermont Mini-Cog to screen
• Anecdotally, providers were happy that the Vermont Mini-Cog takes only ~3 minutes to perform, in contrast to 7-10 minutes for other screening tools
• The majority of providers surveyed feel that routine cognitive impairment screening is beneficial
Future evaluation of effectiveness:
• Primary outcomes
• At what rate are providers screening for cognitive impairment?
• At what rate is the Vermont Mini-Cog being used as the screening tool?
• Compare to existing rates, if possible
• Secondary outcomes
• How many follow-up visits are being scheduled after a patient has a positive cognitive impairment screening?
• How many referrals to the Memory Center are being made?
• How many diagnoses of cognitive impairment or dementia are being made in Colchester Family Medicine patients, either 
in the office or  at the Memory Center?
• Compare to existing rates, if possible
• Tertiary outcomes
• Do Colchester Family Medicine patients experience health benefits associated with earlier diagnosis of cognitive 
impairment and dementia?
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Potential limitations
• The revised Annual Medicare Wellness Visit template is not yet available
• There will likely be some loss of knowledge and momentum around the topic before the visit 
template becomes available
• Many providers are more comfortable or familiar with another screening tool
• Time concerns still exist – there are MANY topics that providers need to address during a 
visit
• Anecdotally, providers are concerned about routinely screening patients who appear 
cognitively intact
• Is 65 too young to start routine screening?
• Providers also have concerns about accessibility of appointments at the Memory Center
• The USPSTF recommendation for routine cognitive impairment screening in older adults is 
Grade I
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Future recommendations
• Continue work on the development of the new Medicare Annual Wellness Visit 
template and integration into Epic
• Retrain Colchester Family Medicine providers and staff as the new template 
becomes available
• Make the training module available to providers outside of Colchester
• Ensure the smooth and timely transition of care from the primary care office to 
the Memory Center in patients who warrant further evaluation and services
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Interview consent form
Thank you for agreeing to be interviewed. This project is a requirement for the 
Family Medicine clerkship. It will be stored on the Dana Library ScholarWorks
website.  Your name will be attached to your interview and you may be cited directly 
or indirectly in subsequent unpublished or published work. The interviewer affirms 
that she has explained the nature and purpose of this project. The interviewee 
affirms that he/she has consented to this interview.
Consented:
• Melissa Barrup, APRN, Candance Fraser, M.D., Alicia Jacobs, M.D., Sean Maloney, M.D., 
William Pendlebury, M.D., Travis Robillard, PA, Marga Sproul, M.D.
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